Is Losartan contraindicated in patients with severe renal failure (eGFR < 30 mL/min/1.73 m²) or on chronic dialysis?

Losartan is NOT Contraindicated in Severe Renal Failure

Losartan can be safely used in patients with severe renal failure (eGFR <30 mL/min/1.73 m²) and those on chronic dialysis without dose adjustment, though careful monitoring is required. 1

Key Evidence from FDA Labeling

The FDA label explicitly states that no dose adjustment is necessary in patients with renal impairment unless the patient is also volume depleted 1. This applies even to severe renal dysfunction, as the pharmacokinetics of losartan and its active metabolite E-3174 are only minimally altered in end-stage renal disease 2.

Specific Populations Where Losartan is Appropriate:

• Hemodialysis patients: Losartan and E-3174 are not dialyzable, so no postdialysis supplementation is required 2
• Severe renal insufficiency (eGFR 10-29 mL/min/1.73 m²): Effective blood pressure control achieved without significant adverse effects 3
• Pediatric exception: The only true contraindication is in pediatric patients <6 years or with eGFR <30 mL/min/1.73 m² 1

Clinical Trial Evidence Supporting Use

The landmark RENAAL trial demonstrated that losartan reduces progression to end-stage renal disease in patients with type 2 diabetes and nephropathy, including those with advanced renal insufficiency 4, 5. Post-hoc analyses confirmed that RAS inhibition slows GFR decline and progression to ESRD even in patients with baseline GFR 10-30 mL/min/1.73 m² 4.

A dedicated study of 112 hypertensive patients with chronic renal insufficiency showed:

• Effective blood pressure reduction across all stages of renal disease 3
• Stable creatinine clearance and GFR during treatment 3
• Only 1 patient required discontinuation due to hyperkalemia (>6 mEq/L) 3

Critical Monitoring Requirements

While not contraindicated, losartan requires vigilant monitoring in severe renal failure:

Monitor for Renal Function Deterioration:

• Acute renal failure risk: Patients with bilateral renal artery stenosis, volume depletion, or severe CHF are at particular risk 6, 1
• Action required: Consider withholding or discontinuing if clinically significant decrease in renal function occurs 1
• Acceptable changes: Serum creatinine increases up to 20% when initiating or intensifying therapy should not be interpreted as progressive deterioration 6

Monitor for Hyperkalemia:

• Risk factors: Chronic kidney disease, concomitant potassium-sparing drugs, or potassium supplements 6, 1
• Action required: Periodic serum potassium monitoring with dose reduction or discontinuation if hyperkalemia develops 1
• Clinical experience: Hyperkalemia requiring discontinuation is rare even in severe renal insufficiency 3

Guideline Recommendations

The 2017 ACC/AHA hypertension guidelines list ARBs (including losartan) as primary agents for hypertension management, with specific cautions but no absolute contraindication in renal failure 6. The guidelines note:

• Increased hyperkalemia risk in CKD patients 6
• Risk of acute renal failure in bilateral renal artery stenosis 6
• Do not use in combination with ACE inhibitors or direct renin inhibitors 6

The 2007 ESH/ESC guidelines emphasize that estimated GFR <60 mL/min/1.73 m² indicates chronic kidney disease stage 3, and values <30 mL/min/1.73 m² indicate stage 4, but these are indications for careful monitoring rather than contraindication to RAS inhibition 6.

Special Considerations

Volume depletion: The recommended starting dose is 25 mg daily in patients with possible intravascular depletion (e.g., on diuretic therapy) to prevent symptomatic hypotension 1

Hepatic impairment: Dose reduction to 25 mg daily is required for mild-to-moderate hepatic impairment, which is a more significant concern than renal impairment 1

Erythropoietin resistance: High-dose losartan (100 mg/day) may increase erythropoietin requirements in hemodialysis patients, though this should not preclude use when indicated 7